Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

4(80.0%)

N/A

1(20.0%)

5Total

Phase 2(4)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03775460Not ApplicableActive Not Recruiting

Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum

Role: collaborator

NCT06514560Recruiting

OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients

Role: collaborator

NCT00919776Phase 2Completed

Ciclosporin in the Management of Chronic or Recurrent Erythema Nodosum Leprosum

Role: collaborator

NCT00919451Phase 2Completed

Ciclosporin in the Management of Steroid Resistant Type 1 Reactions in Leprosy

Role: collaborator

NCT00919815Phase 2Completed

Ciclosporin in the Management of New Type 1 Reactions in Leprosy

Role: collaborator

NCT00919542Phase 2Completed

Ciclosporin in the Management of New Erythema Nodosum Leprosum

Role: collaborator

All 6 trials loaded